Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema

Journal of Immunology

Volumn 175, Issue 10, 2005, Pages 6968-6975

  Ishii, Yukio ^a   Itoh, Ken ^a   Morishima, Yuko ^a   Kimura, Toru ^a   Kiwamoto, Takumi ^a   Iizuka, Takashi ^a   Hegab, Ahmed E ^a   Hosoya, Tomonori ^a   Nomura, Akihiro ^a   Sakamoto, Tohru ^a   Yamamoto, Masayuki ^a   Sekizawa, Kiyohisa ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ELASTASE; PROTEINASE; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE EXPRESSION; KNOCKOUT MOUSE; LUNG ALVEOLUS MACROPHAGE; LUNG EMPHYSEMA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; TISSUE INJURY; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; WILD TYPE;

EID: 27744450995     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.10.6968     Document Type: Article

References (40)

1. Murray, C. J., and A. D. Lopez. 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504.
2. Barnes, P. J. 2000. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343: 269-280.
3. Repine, J. E., A. Bast, and I. Lankhorst. 1997. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 156: 341-357.
4. Barnes, P. J. 2003. New concepts in chronic obstructive pulmonary disease. Annu. Rev. Med 54: 113-129.
5. Siafakas, N. M., and E. G. Tzortzaki. 2002. Few smokers develop COPD: why? Respir. Med. 96: 615-624.
6. Hubbard, R. C., and R. G. Crystal. 1991. Antiproteases. In The Lung: Scientific Foundations. R. G. Crystal, J. B. West, and P. J. Barnes, eds. Raven Press. New York. pp. 1775-1787.
7. McElvaney, N. G., and R. G. Crystal. 1997. Inherited susceptibility of the lung to proteolytic injury. In The Lung: Scientific Foundations. R. G. Crystal, J. B. West, E. R. Weibel, and P. J. Barnes, eds. Lippincott-Raven. Philadelphia, pp. 2537-2553.
8. Itoh, K., T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, et al. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236: 313-322.
9. Ishii, T., K. Itoh, S. Takahashi, H. Sato, T. Yanagawa, Y. Katoh, S. Bannai, and M. Yamamoto. 2000. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 275: 16023-16029.
10. Itoh, K., K. I. Tong, and M. Yamamoto. 2004. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radical Biol. Med. 36: 1208-1213.
11. Kobayashi, A., T. Ohta, and M. Yamamoto. 2004. Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol. 378: 273-286.
12. Itoh, K., N. Wakabayashi, Y. Katoh, T. Ishii, T. O'Connor, and M. Yamamoto. 2003. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 8: 379-391.
13. McMahon, M., K. Itoh, M. Yamamoto, and J. D. Hayes. 2003. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem. 278: 21592-21600.
14. Yoh, K., K. Itoh, A. Enomoto, A. Hirayama, N. Yamaguchi, M. Kobayashi, N. Morito, A. Koyama, M. Yamamoto, and S. Takahashi. 2001. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int. 60: 1343-1353.
15. Chan, K., X. D. Han, and Y. W. Kan. 2001. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA 98: 4611-4616.
16. Enomoto, A., K. Itoh, E. Nagayoshi, J. Haruta, T. Kimura, T. O'Connor, T. Harada, and M. Yamamoto. 2001. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59: 169-177.
17. Aoki, Y., H. Sato, N. Nishimura, S. Takahashi, K. Itoh, and M. Yamamoto. 2001. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol. Appl. Pharmacol. 173: 154-160.
18. Ramos-Gomez, M., M. K. Kwak, P. M. Dolan, K. Itoh, M. Yamamoto, P. Talalay, and T. W. Kensler. 2001. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA 98: 3410-3415.
19. Chan, K., and Y. W. Kan. 1999. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. USA 96: 12731-12736.
20. Cho, H. Y., A. E. Jedlicka, S. P. Reddy, T. W. Kensler, M. Yamamoto, L. Y. Zhang, and S. R. Kleeberger. 2002. Role of NRF2 in protection against hyperoxic lung injury in mice Am. J. Respir. Cell Mol. Biol. 26: 175-182.
21. 2. Mol. Cell. Biol. 24: 36-45.
22. 2 and Nrf2 pathways in protection against acute lung injury. Am. J. Respir. Crit. Care Med. 171: 1260-1266.
23. Hayes, J. A., A. Korthy, and G. L. Snider. 1975. The pathology of elastase-induced panacinar emphysema in hamsters. J. Pathol. 117: 1-14.
24. Kaplan, P. D., C. Kuhn, and J. A. Pierce. 1973. The induction of emphysema with elastase. I. The evolution of the lesion and the influence of serum. J. Lab. Clin. Med. 82: 349-356.
25. Saetta, M., R. J. Shiner, G. E. Angus, W. D. Kim, N. S. Wang, M. King, H. Ghezzo, and M. G. Cosio. 1985. Destructive index: a measurement of lung parenchymal destruction in smokers. Am. Rev. Respir. Dis. 131: 764-769.
26. Sakamaki, P., A. Ishizaka, T. Urano, K. Sayama, H. Nakamura, T. Terashima, Y. Waki, S. Tasaka, N. Hasegawa, K. Sato, et al. 1996. Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am. J. Respir. Crit. Care Med. 153: 391-397.
27. Dietz, A. A., H. M. Rubinstein, and L. Hodges. 1976. Use of α-N-benzoyl-L-arginine-p-nitroanilide as trypsin substrate in estimation of α1-antitrypsin. Clin. Chem. 22: 1754-1755.
28. Kiel, M. J., Ö. H. Yilmaz, T. Iwashita, O. H. Yilmaz, C. Terhorst, and S. J. Morrison. 2005. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121: 1109-1121.
29. Lucey, E. C., P. J. Stone, T. G. Christensen, R. Breuer, and G. L. Snider. 1988. An 18-month study of the effects on hamster lungs of intratracheally administered human neutrophil elastase. Exp. Lung Res. 14: 671-686.
30. Stone, P. J., E. C. Lucey, J. D. Galore, M. P. McMahon, G. L. Snider, and C. Franzblau. 1988. Defenses of the hamster lung against human neutrophil and porcine pancreatic elastase. Respiration 54: 1-15.
31. Lucey, E. C., J. Keane, P. P. Kuang, G. L. Snider, and R. H. Goldstein. 2002. Severity of elastase-induced emphysema is decreased in tumor necrosis factor-α and interleukin-1β receptor-deficient mice. Lab. Invest. 82: 79-85.
32. Snider, G. L., and C. B. Sherter. 1977. A one-year study of the evolution of elastase-induced emphysema in hamsters. J. Appl. Physiol. 43: 721-729.
33. McElvaney, N. G., and R. G. Crystal. 1997. Inherited susceptibility of the lung to proteolytic injury. In The Lung: Scientific Foundations. R. G. Crystal, J. B. West, E. R. Weibel, and P. J. Barnes, eds. Lippincott-Raven. Philadelphia, pp. 2219-2235.
34. Jin, F. Y., C. Nathan, D. Radzioch, and A. Ding. 1997. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88: 417-426.
35. Abbinante-Nissen, J. M., L. G. Simpson, and G. D. Leikauf. 1993. Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am. J. Physiol. 265: L286-L292.
36. Sallenave, J. M., J. Shulmann, J. Crossley, M. Jordana, J. Gauldie. 1994. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol. 11: 733-741.
37. Betsuyasu, T., K. Takeyabu, M. Tanino, and M. Nishimura. 2002. Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema. Eur. Respir. J. 19: 1051-1057.
38. Odaka, C., T. Mizuochi, J. Yang, and A. Ding. 2003. Murine macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: implications for resolution of the inflammatory response. J. Immunol. 171: 1507-1514.
39. Lentsch, A. B., J. A. Jordan, B. J. Czermak, K. M. Diehl, E. M. Younkin, V. Sarma, and P. A. Ward. 1999. Inhibition of NF-κB activation and augmentation of IκBβ by secretory leukocyte protease inhibitor during lung inflammation. Am. J. Pathol. 154: 239-247.
40. Chen, X. L., and C. Kunsch. 2004. Induction of cytoprotective genes through nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr. Pharm. Des. 10: 879-891.